Gregory A. Wiseman
About
Gregory A. Wiseman is a scholar working on Pathology and Forensic Medicine, Radiology, Nuclear Medicine and Imaging and Oncology.
According to data from OpenAlex, Gregory A. Wiseman has authored 113 papers receiving a total of 8.5k indexed citations (citations by other indexed papers that have themselves been cited), including 61 papers in Pathology and Forensic Medicine, 52 papers in Radiology, Nuclear Medicine and Imaging and 36 papers in Oncology. Recurrent topics in Gregory A. Wiseman's work include Lymphoma Diagnosis and Treatment (61 papers), Radiopharmaceutical Chemistry and Applications (31 papers) and Monoclonal and Polyclonal Antibodies Research (21 papers). Gregory A. Wiseman is often cited by papers focused on Lymphoma Diagnosis and Treatment (61 papers), Radiopharmaceutical Chemistry and Applications (31 papers) and Monoclonal and Polyclonal Antibodies Research (21 papers). Gregory A. Wiseman collaborates with scholars based in United States, Switzerland and Canada. Gregory A. Wiseman's co-authors include Thomas E. Witzig, Leo I. Gordon, Christos Emmanouilides, Brian P. Mullan, Pratik S. Multani, Antonio J Grillo-López, Christine A. White, Stewart Spies, Christine A. White and Myron S. Czuczman and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.
In The Last Decade
Gregory A. Wiseman
112 papers receiving 8.2k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Gregory A. Wiseman United States | 43 | 4.1k | 3.6k | 2.6k | 2.0k | 1.3k | 113 | 8.5k | ||
| Malik E. Juweid United States | 31 | 4.7k 1.2× | 3.5k 1.0× | 2.7k 1.0× | 1.8k 0.9× | 1.7k 1.3× | 126 | 8.1k | ||
| Peter Mauch United States | 54 | 5.1k 1.3× | 1.5k 0.4× | 3.7k 1.4× | 2.1k 1.1× | 1.8k 1.4× | 242 | 10.8k | ||
| Donald A. Podoloff United States | 42 | 2.2k 0.5× | 4.0k 1.1× | 2.9k 1.1× | 3.5k 1.7× | 482 0.4× | 135 | 9.9k | ||
| Yoshihiro Matsuno Japan | 59 | 2.3k 0.6× | 1.1k 0.3× | 5.2k 2.0× | 5.6k 2.8× | 1.8k 1.4× | 381 | 13.0k | ||
| Moody D. Wharam United States | 53 | 2.5k 0.6× | 682 0.2× | 2.4k 0.9× | 5.8k 2.9× | 1.5k 1.1× | 184 | 9.3k | ||
| Massimo Federico Italy | 45 | 8.0k 2.0× | 1.5k 0.4× | 5.5k 2.1× | 2.5k 1.2× | 2.3k 1.8× | 288 | 12.0k | ||
| Yoshiya Yamada United States | 62 | 3.6k 0.9× | 2.1k 0.6× | 1.9k 0.7× | 7.4k 3.7× | 476 0.4× | 280 | 14.0k | ||
| Paul J. Kurtin United States | 64 | 5.1k 1.3× | 687 0.2× | 3.6k 1.4× | 1.1k 0.6× | 1.4k 1.1× | 235 | 11.4k | ||
| Young Hyeh Ko South Korea | 53 | 6.6k 1.6× | 502 0.1× | 5.7k 2.2× | 1.1k 0.5× | 1.3k 1.0× | 364 | 10.6k | ||
| Annibale Versari Italy | 34 | 1.2k 0.3× | 1.4k 0.4× | 990 0.4× | 1.7k 0.8× | 623 0.5× | 162 | 4.2k |
Countries citing papers authored by Gregory A. Wiseman
Since
Specialization
Citations
This map shows the geographic impact of Gregory A. Wiseman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gregory A. Wiseman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gregory A. Wiseman more than expected).
Fields of papers citing papers by Gregory A. Wiseman
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Gregory A. Wiseman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gregory A. Wiseman. The network helps show where Gregory A. Wiseman may publish in the future.
Co-authorship network of co-authors of Gregory A. Wiseman
This figure shows the co-authorship network connecting the top 25 collaborators of Gregory A. Wiseman. A scholar is included among the top collaborators of Gregory A. Wiseman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gregory A. Wiseman. Gregory A. Wiseman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Atherton, Pamela J., et al.. (2024). The asymptomatic follicular lymphoma (AFL) trial: single-agent rituximab immunotherapy versus 90Y-ibritumomab tiuxetan radioimmunotherapy (RIT) for patients with new, untreated follicular lymphoma. Leukemia & lymphoma. 65(3). 333–338.
2.
Youland, Ryan S., Annie T. Packard, Andrea Arnett, et al.. (2017). 18F-FDG PET response and clinical outcomes after stereotactic body radiation therapy for metastatic melanoma. Advances in Radiation Oncology. 2(2). 204–210.
3.
Moreno-Luna, Laura E., Ju Dong Yang, William Sánchez, et al.. (2012). Efficacy and Safety of Transarterial Radioembolization Versus Chemoembolization in Patients With Hepatocellular Carcinoma. CardioVascular and Interventional Radiology. 36(3). 714–723.
4.
Ahmed, Kamran A., Brian J. Davis, Torrence M. Wilson, et al.. (2012). Progress in Gene Therapy for Prostate Cancer. SHILAP Revista de lepidopterología. 2. 172–172.
5.
Bogsrud, Trond Velde, Ian Hay, Dimitrios Karantanis, et al.. (2011). Prognostic value of 18F-fluorodeoxyglucose-positron emission tomography in patients with differentiated thyroid carcinoma and circulating antithyroglobulin autoantibodies. Nuclear Medicine Communications. 32(4). 245–251.
6.
Anthony, Lowell, Jonathan Strosberg, David S. Klimstra, et al.. (2010). The NANETS Consensus Guidelines for the Diagnosis and Management of Gastrointestinal Neuroendocrine Tumors (NETs). Pancreas. 39(6). 767–774.
7.
Horning, Sandra J., Malik E. Juweid, Heiko Schöder, et al.. (2009). Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study. Blood. 115(4). 775–777.
8.
Fleming, Chad J., James C. Andrews, Gregory A. Wiseman, Denise N. Gansen, & Lewis R. Roberts. (2009). Hepatic Vein Tumor Thrombus as a Risk Factor for Excessive Pulmonary Deposition of Microspheres during TheraSphere Therapy for Unresectable Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology. 20(11). 1460–1463.
9.
Bogsrud, Trond Velde, Dimitrios Karantanis, Mark A. Nathan, et al.. (2008). 18 F-FDG PET in the Management of Patients with Anaplastic Thyroid Carcinoma. Thyroid. 18(7). 713–719.
10.
Juweid, Malik E., Sigrid Stroobants, Otto S. Hoekstra, et al.. (2007). Use of Positron Emission Tomography for Response Assessment of Lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. Journal of Clinical Oncology. 25(5). 571–578.
11.
Witzig, Thomas E., Arturo Molina, Leo I. Gordon, et al.. (2007). Long‐term responses in patients with recurring or refractory B‐cell non‐Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer. 109(9). 1804–1810.
12.
Wiseman, Gregory A., Peter S. Conti, Katie D. Vo, et al.. (2007). Weight-Based Dosing of Yttrium 90 Ibritumomab Tiuxetan in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma. Clinical Lymphoma & Myeloma. 7(8). 514–517.
13.
Karantanis, Dimitrios, Trond Velde Bogsrud, Gregory A. Wiseman, et al.. (2007). Clinical Significance of Diffusely Increased 18F-FDG Uptake in the Thyroid Gland. Journal of Nuclear Medicine. 48(6). 896–901.
14.
Mullan, Brian P., et al.. (2006). 18F FDG PET/CT imaging of primary extradrenal paragangliomas. Inorganic Chemistry. 47(17). 7193–8.
15.
Rodriguez, Vilmarie, et al.. (2005). Low toxicity and efficacy of 153samarium‐EDTMP and melphalan as a conditioning regimen for secondary acute myelogenous leukemia. Pediatric Transplantation. 9(1). 122–126.
16.
Schilder, Russell J., Arturo Molina, Nancy L. Bartlett, et al.. (2004). Follow-Up Results of a Phase II Study of Ibritumomab Tiuxetan Radioimmunotherapy in Patients with Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin's Lymphoma and Mild Thrombocytopenia. Cancer Biotherapy and Radiopharmaceuticals. 19(4). 478–481.
17.
Anderson, Peter M., Gregory A. Wiseman, Angela Dispenzieri, et al.. (2002). High-Dose Samarium-153 Ethylene Diamine Tetramethylene Phosphonate: Low Toxicity of Skeletal Irradiation in Patients With Osteosarcoma and Bone Metastases. Journal of Clinical Oncology. 20(1). 189–196.
18.
Wiseman, Gregory A., Bryan R. Leigh, William D. Erwin, et al.. (2002). Radiation dosimetry results for zevalin radioimmunotherapy of rituximab-refractory non-hodgkin lymphoma. Cancer. 94(S4). 1349–1357.
19.
Wiseman, Gregory A., Christine A. White, Michael Stabin, et al.. (2000). Phase I/II 90 Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. European Journal of Nuclear Medicine and Molecular Imaging. 27(7). 766–777.
20.
Krowka, Michael J., Gregory A. Wiseman, Jeffery L. Steers, & Russell H. Wiesner. (1999). Late recurrence and rapid evolution of severe hepatopulmonary syndrome after liver transplantation. Liver Transplantation and Surgery. 5(5). 451–453.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Malik E. Juweid Breakdown of academic impact, for papers by Peter Mauch Breakdown of academic impact, for papers by Donald A. Podoloff Breakdown of academic impact, for papers by Yoshihiro Matsuno Breakdown of academic impact, for papers by Moody D. Wharam Breakdown of academic impact, for papers by Massimo Federico Breakdown of academic impact, for papers by Yoshiya Yamada Breakdown of academic impact, for papers by Paul J. Kurtin Breakdown of academic impact, for papers by Young Hyeh Ko Breakdown of academic impact, for papers by Annibale Versari